This Figure is similar to Figure 38, with rivaroxaban, showing the results for the components of the primary outcomes of stroke or systemic embolism. As with the other factor Xa inhibitor, rivaroxaban, there was a reduction in hemorrhagic stroke compared to warfarin, but no reduction in ischemic stroke.  Why this was so is unclear, but it is important for physicians to note that for both factor Xa inhibitors, ischemic stroke is reduced to the same extent as with warfarin – and warfarin is considered to have a good efficacy profile in this setting.

 Reiffel JA. Am J Med 2013; 126: 00-00.